Cargando…

Soluble interleukin-1 receptor type 2 plasma levels in Parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation

Introduction: Systemic inflammation promotes neurodegeneration in Parkinson’s disease (PD). Interleukin-1 receptor type 2 (sIL-1R2) plasma levels increase during inflammation. Data on sIL-1R2 in PD patients and its relationship with PD cardiac autonomic profile are limited, given the possible anti-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiffer, Dana, Zamunér, Antonio Roberto, Minonzio, Maura, Bulgheroni, Mara, Porta, Alberto, Leone, Roberto, Bottazzi, Barbara, Garlanda, Cecilia, Colotta, Francesco, Barbic, Franca, Mantovani, Alberto, Furlan, Raffaello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468972/
https://www.ncbi.nlm.nih.gov/pubmed/37664433
http://dx.doi.org/10.3389/fphys.2023.1168652
_version_ 1785099341815349248
author Shiffer, Dana
Zamunér, Antonio Roberto
Minonzio, Maura
Bulgheroni, Mara
Porta, Alberto
Leone, Roberto
Bottazzi, Barbara
Garlanda, Cecilia
Colotta, Francesco
Barbic, Franca
Mantovani, Alberto
Furlan, Raffaello
author_facet Shiffer, Dana
Zamunér, Antonio Roberto
Minonzio, Maura
Bulgheroni, Mara
Porta, Alberto
Leone, Roberto
Bottazzi, Barbara
Garlanda, Cecilia
Colotta, Francesco
Barbic, Franca
Mantovani, Alberto
Furlan, Raffaello
author_sort Shiffer, Dana
collection PubMed
description Introduction: Systemic inflammation promotes neurodegeneration in Parkinson’s disease (PD). Interleukin-1 receptor type 2 (sIL-1R2) plasma levels increase during inflammation. Data on sIL-1R2 in PD patients and its relationship with PD cardiac autonomic profile are limited, given the possible anti-inflammatory effect of vagal activation. Previously, automated mechanical peripheral somatosensory stimulation (AMPSS) enhanced cardiac vagal modulation. Objectives were to 1) evaluate sIL-1R2 plasma concentrations in PD patients and healthy controls and 2) investigate the correlations between sIL-1R2 and cardiac autonomic indices obtained by spectrum analysis of heart rate variability before and after AMPSS. Methods: sIL-1R2 plasma levels were assessed in 48 PD patients and 50 healthy controls. Electrocardiogram and beat-by-beat arterial pressure were recorded at baseline and after 5 AMPSS sessions in 16 PD patients. Results: PD patients had higher sIL-1R2 levels than controls. In the PD subgroup, an inverse correlation between sIL-1R2 and HFnu was found. There was a negative correlation between changes induced by AMPSS on HFnu and sIL-1R2. Discussion: Higher sIL-1R2 levels in PD patients reflect the inflammatory dysregulation associated with the disease. In PD patients, higher sIL-1R2 was associated with reduced cardiovagal tone. Increased cardiovagal modulation following AMPSS was associated with lower sIL-1R2 levels in Parkinson’s disease patients, suggesting inflammatory state improvement.
format Online
Article
Text
id pubmed-10468972
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104689722023-09-01 Soluble interleukin-1 receptor type 2 plasma levels in Parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation Shiffer, Dana Zamunér, Antonio Roberto Minonzio, Maura Bulgheroni, Mara Porta, Alberto Leone, Roberto Bottazzi, Barbara Garlanda, Cecilia Colotta, Francesco Barbic, Franca Mantovani, Alberto Furlan, Raffaello Front Physiol Physiology Introduction: Systemic inflammation promotes neurodegeneration in Parkinson’s disease (PD). Interleukin-1 receptor type 2 (sIL-1R2) plasma levels increase during inflammation. Data on sIL-1R2 in PD patients and its relationship with PD cardiac autonomic profile are limited, given the possible anti-inflammatory effect of vagal activation. Previously, automated mechanical peripheral somatosensory stimulation (AMPSS) enhanced cardiac vagal modulation. Objectives were to 1) evaluate sIL-1R2 plasma concentrations in PD patients and healthy controls and 2) investigate the correlations between sIL-1R2 and cardiac autonomic indices obtained by spectrum analysis of heart rate variability before and after AMPSS. Methods: sIL-1R2 plasma levels were assessed in 48 PD patients and 50 healthy controls. Electrocardiogram and beat-by-beat arterial pressure were recorded at baseline and after 5 AMPSS sessions in 16 PD patients. Results: PD patients had higher sIL-1R2 levels than controls. In the PD subgroup, an inverse correlation between sIL-1R2 and HFnu was found. There was a negative correlation between changes induced by AMPSS on HFnu and sIL-1R2. Discussion: Higher sIL-1R2 levels in PD patients reflect the inflammatory dysregulation associated with the disease. In PD patients, higher sIL-1R2 was associated with reduced cardiovagal tone. Increased cardiovagal modulation following AMPSS was associated with lower sIL-1R2 levels in Parkinson’s disease patients, suggesting inflammatory state improvement. Frontiers Media S.A. 2023-08-16 /pmc/articles/PMC10468972/ /pubmed/37664433 http://dx.doi.org/10.3389/fphys.2023.1168652 Text en Copyright © 2023 Shiffer, Zamunér, Minonzio, Bulgheroni, Porta, Leone, Bottazzi, Garlanda, Colotta, Barbic, Mantovani and Furlan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Shiffer, Dana
Zamunér, Antonio Roberto
Minonzio, Maura
Bulgheroni, Mara
Porta, Alberto
Leone, Roberto
Bottazzi, Barbara
Garlanda, Cecilia
Colotta, Francesco
Barbic, Franca
Mantovani, Alberto
Furlan, Raffaello
Soluble interleukin-1 receptor type 2 plasma levels in Parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation
title Soluble interleukin-1 receptor type 2 plasma levels in Parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation
title_full Soluble interleukin-1 receptor type 2 plasma levels in Parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation
title_fullStr Soluble interleukin-1 receptor type 2 plasma levels in Parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation
title_full_unstemmed Soluble interleukin-1 receptor type 2 plasma levels in Parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation
title_short Soluble interleukin-1 receptor type 2 plasma levels in Parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation
title_sort soluble interleukin-1 receptor type 2 plasma levels in parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468972/
https://www.ncbi.nlm.nih.gov/pubmed/37664433
http://dx.doi.org/10.3389/fphys.2023.1168652
work_keys_str_mv AT shifferdana solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT zamunerantonioroberto solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT minonziomaura solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT bulgheronimara solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT portaalberto solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT leoneroberto solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT bottazzibarbara solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT garlandacecilia solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT colottafrancesco solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT barbicfranca solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT mantovanialberto solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation
AT furlanraffaello solubleinterleukin1receptortype2plasmalevelsinparkinsonsdiseaserelationshipwithcardiacautonomicprofilebeforeandafterperipheralmechanicalsomatosensorystimulation